United Therapeutics Co. (NASDAQ:UTHR) Director Raymond Dwek Sells 4,600 Shares of Stock

United Therapeutics Co. (NASDAQ:UTHR) Director Raymond Dwek sold 4,600 shares of the business’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $116.81, for a total transaction of $537,326.00. Following the transaction, the director now directly owns 4,600 shares of the company’s stock, valued at $537,326. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Shares of United Therapeutics stock opened at $121.00 on Wednesday. United Therapeutics Co. has a 52 week low of $74.31 and a 52 week high of $127.79. The company has a current ratio of 8.91, a quick ratio of 8.46 and a debt-to-equity ratio of 0.27. The stock has a market cap of $5.27 billion, a PE ratio of 10.09 and a beta of 0.87. The company’s 50-day moving average price is $118.93 and its two-hundred day moving average price is $102.15.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.12 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.43 by $0.69. The company had revenue of $356.30 million for the quarter, compared to analysts’ expectations of $343.68 million. United Therapeutics had a net margin of 36.59% and a return on equity of 19.19%. The business’s revenue was down 1.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.58 EPS. On average, equities analysts predict that United Therapeutics Co. will post 10.4 EPS for the current fiscal year.

UTHR has been the topic of a number of recent analyst reports. TheStreet raised United Therapeutics from a “c” rating to a “b” rating in a report on Wednesday, April 29th. HC Wainwright lifted their target price on United Therapeutics from $85.00 to $125.00 and gave the company a “neutral” rating in a research note on Thursday, June 25th. Oppenheimer began coverage on United Therapeutics in a research note on Wednesday, June 24th. They issued a “buy” rating and a $155.00 price target for the company. Credit Suisse Group lifted their price objective on shares of United Therapeutics from $129.00 to $145.00 and gave the company an “outperform” rating in a research note on Thursday, June 25th. Finally, Cowen reiterated a “buy” rating and issued a $145.00 target price on shares of United Therapeutics in a research report on Friday, June 12th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company. United Therapeutics has a consensus rating of “Buy” and an average target price of $137.00.

Several institutional investors and hedge funds have recently added to or reduced their stakes in UTHR. APG Asset Management N.V. acquired a new position in shares of United Therapeutics in the 1st quarter worth $80,654,000. Norges Bank acquired a new position in shares of United Therapeutics in the 4th quarter valued at $46,489,000. Renaissance Technologies LLC increased its stake in United Therapeutics by 10.3% in the 4th quarter. Renaissance Technologies LLC now owns 3,544,433 shares of the biotechnology company’s stock worth $312,194,000 after purchasing an additional 332,155 shares in the last quarter. Nuveen Asset Management LLC raised its holdings in United Therapeutics by 48.9% during the 1st quarter. Nuveen Asset Management LLC now owns 776,413 shares of the biotechnology company’s stock worth $73,624,000 after buying an additional 255,101 shares during the period. Finally, AJO LP purchased a new stake in United Therapeutics during the fourth quarter valued at about $20,146,000. 98.11% of the stock is owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Featured Story: Do stock splits help investors?

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.